Episurf Medical’s toe implant – planned 510(k) application Q2 2023
Episurf Medical (NASDAQ: EPIS B) today announces that the company plans to file a 510(k) submission to the US FDA during Q2 2023 for the toe implant the company is currently developing. The company aims to receive market clearance to be able to launch the product on the US market during 2024. The implant is intended to treat osteoarthritis (hallux rigidus) in the big toe, and more specifically of the so-called 1st MTP joint. It is based on Episurf Medical’s proprietary technology for patient-specific design of implants and surgical instruments. “I am pleased with having our plans